US FDA Meets OTC Monograph Program Overhaul Deadlines But Notes Facility Fees Behind Schedule

FDA Office of Nonprescription Drugs explains in its proposed commitment letter for fiscal years 2026-2030, based in part on suggestions by stakeholders, that it will heighten its attention to collecting those fees.